Literature DB >> 10667469

A case-control study of galactose consumption and metabolism in relation to ovarian cancer.

D W Cramer1, E R Greenberg, L Titus-Ernstoff, R F Liberman, W R Welch, E Li, W G Ng.   

Abstract

Consumption or metabolism of dairy sugar and ovarian cancer have been linked based on evidence that galactose may be toxic to ovarian germ cells and that ovarian cancer is induced in animals by depletion of oocytes. We assessed consumption of dairy products and obtained blood for biochemical and molecular genetic assessment of galactose metabolism in 563 women with newly diagnosed epithelial ovarian cancer and 523 control women selected either by random digit dialing or through lists of residents in eastern Massachusetts and New Hampshire. We observed no significant differences between cases and controls in usual consumption of various types of dairy products or total daily lactose (the principal source of galactose in the diet); nor did we find that RBC activity of either galactose-1-phosphate uridyl transferase (GALT) or galactokinase differed. The mean (and SE) activity of uridine diphospho-galactose 4'-epimerase (in micromoles per hour per gram of hemoglobin) was, however, significantly lower (P < 0.005) in cases compared with controls, 20.32 (0.31) versus 21.64 (0.36). Ovarian cancer cases were also more likely to carry the N314D polymorphism of the GALT gene, generally predisposing to lower GALT activity. The difference was most evident for endometrioid and clear cell types of ovarian cancer, in which 3.9% of cases were found to be homozygous for N314D compared with 0.4% of controls, yielding an odds ratio and 95% confidence interval of 14.17 (2.62-76.60). We conclude that, whereas adult consumption of lactose carries no clear risk for the disease, certain genetic or biochemical features of galactose metabolism may influence disease risk for particular types of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667469

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  Duarte galactose-1-phosphate uridyl transferase genotypes are not associated with ovarian cancer risk.

Authors:  Melissa A Merritt; Joanne Kotsopoulos; Daniel W Cramer; Susan E Hankinson; Kathryn L Terry; Shelley S Tworoger
Journal:  Fertil Steril       Date:  2012-06-29       Impact factor: 7.329

2.  Dairy foods and nutrients in relation to risk of ovarian cancer and major histological subtypes.

Authors:  Melissa A Merritt; Daniel W Cramer; Allison F Vitonis; Linda J Titus; Kathryn L Terry
Journal:  Int J Cancer       Date:  2012-07-24       Impact factor: 7.396

3.  Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.

Authors:  Louis Dubeau
Journal:  Transl Cancer Res       Date:  2015-02       Impact factor: 1.241

4.  Milk Consumption Decreases Risk for Breast Cancer in Korean Women under 50 Years of Age: Results from the Health Examinees Study.

Authors:  Woo-Kyoung Shin; Hwi-Won Lee; Aesun Shin; Jong-Koo Lee; Daehee Kang
Journal:  Nutrients       Date:  2019-12-21       Impact factor: 5.717

5.  Dairy consumption and ovarian cancer risk in the Netherlands Cohort Study on Diet and Cancer.

Authors:  M Mommers; L J Schouten; R A Goldbohm; P A van den Brandt
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

6.  Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer.

Authors:  Hongyu Xie; Wenjie Wang; Fengyu Sun; Kui Deng; Xin Lu; Huijuan Liu; Weiwei Zhao; Yuanyuan Zhang; Xiaohua Zhou; Kang Li; Yan Hou
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

7.  Compound Fuling Granule Suppresses Ovarian Cancer Development and Progression by disrupting mitochondrial function, galactose and fatty acid metabolism.

Authors:  Shanming Ruan; Zhiqian Zhang; Xinxin Tian; Dawei Huang; Wenhong Liu; Bo Yang; Minhe Shen; Fangfang Tao
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.